These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8359732)

  • 21. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
    Yenisey C; Güner G
    Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
    [No Abstract]   [Full Text] [Related]  

  • 23. An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer.
    Cooper EH; Forbes MA; Hancock AK; Price JJ; Parker D
    Br J Cancer; 1989 May; 59(5):797-800. PubMed ID: 2736216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
    Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E
    Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
    Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
    Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple method for comparing reliability of two serum tumour markers in breast carcinoma.
    O'Brien DP; Gough DB; Skehill R; Grimes H; Given HF
    J Clin Pathol; 1994 Feb; 47(2):134-7. PubMed ID: 8132827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer].
    Ammon A; Eiffert H; Alhusen R; Weber M; Rümelin B; Groh E; Bartsch H; Marschner N; Nagel GA; Krieger G
    Onkologie; 1990 Jun; 13(3):210-4. PubMed ID: 2204009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
    Gion M; Mione R; Gatti C; Dittadi R; Leon A; Nascimben O; Pizzorno B; Bruscagnin G
    Tumori; 1990 Aug; 76(4):360-4. PubMed ID: 2399565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemistry and molecular biology of MCA.
    Maurer A; Burckhardt J
    Int J Biol Markers; 1993; 8(2):108-12. PubMed ID: 8366293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.
    Laurence V; Forbes MA; Cooper EH
    Br J Cancer; 1991 Jun; 63(6):1000-4. PubMed ID: 2069833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.
    Stierer M; Rosen HR; Forster E; Moroz C
    Breast Cancer Res Treat; 1991 Nov; 19(3):283-8. PubMed ID: 1777647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.
    Garcia MB; Blankenstein MA; van der Wall E; Nortier JW; Schornagel JH; Thijssen JH
    Breast Cancer Res Treat; 1990 Dec; 17(2):69-76. PubMed ID: 2096994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
    Cohen AD; Gopas J; Karplus G; Cohen Y
    Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial serum MCA measurements in the follow-up of breast cancer patients.
    Merimsky O; Inbar M; Hareuveni M; Witenberg B; Wolman Y; Chaitchik S
    Eur J Cancer; 1991; 27(11):1440-4. PubMed ID: 1835861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.